
News Releases
View all Historical Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 25, 2023
Vaccines stable for at least two years when stored at 40 degrees Celsius / 104 degrees Fahrenheit Only subunit (protein) vaccine platform shown to protect against potentially lethal Ebola and...
-
Sep 22, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Aug 21, 2023
Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Aug 10, 2023
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J., Aug. 10, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...
-
Jul 11, 2023
Clear biological signal demonstrated; additional patients to be enrolled PRINCETON, N.J., July 11, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...
-
May 16, 2023
Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims PRINCETON, N.J., May 16, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the...
-
May 15, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
May 11, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
May 9, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
May 5, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
May 4, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
May 3, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
May 1, 2023
Phase 2/3-Ready Orphan Disease Program Complements Company's Existing Late-Stage Rare Disease Pipeline PRINCETON, N.J., May 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the...
-
Apr 24, 2023
Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N.J., April 24, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company),...
-
Apr 14, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Apr 5, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Apr 3, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Mar 31, 2023
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Mar 17, 2023
On February 9, 2023 Soligenix, Inc. announced that it intended to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock...
-
Mar 9, 2023
Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N.J., March 9, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company),...
-
Feb 14, 2023
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval PRINCETON, N.J., Feb. 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)...
-
Feb 9, 2023
Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023 PRINCETON, N.J., Feb. 9, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage...
-
Jan 19, 2023
Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J., Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or...
-
Dec 23, 2022
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Dec 20, 2022
RiVax®-Vaccinated NHP survival was statistically significantly correlated with an epitope-specific serum assay ("EPICC") prior to challenge Correlates of protection are essential to support...